Online GLP-1 Programs in Indiana

Insurance

Does Indiana Medicaid cover GLP-1s?

Indiana Medicaid, including the Healthy Indiana Plan, does not cover GLP-1s for adult weight loss. The state's own prior-authorization criteria require a diabetes or related diagnosis, with no obesity pathway for members 21 and older (Indiana Medicaid GLP-1 criteria, 2025). A 2025 bill to mandate coverage did not pass after the state estimated it would cost $11 million to $70 million a year. GLP-1s for type 2 diabetes are covered, as federal law requires.

Online Access

Getting a GLP-1 online in Indiana

GLP-1s are not controlled substances, so Indiana allows them to be prescribed via telehealth without a prior in-person visit, provided an Indiana-licensed clinician meets the standard of care (Indiana Code 25-1-9.5). Online programs can serve residents statewide through an Indiana-licensed prescriber.

Compounding

Compounded semaglutide & tirzepatide in Indiana

Routine compounding of semaglutide and tirzepatide ended after the FDA resolved the shortages in early 2025 (FDA, 2025). Indiana adds no special carve-out beyond the federal 503A/503B framework, so compounding is limited to documented, patient-specific clinical need.

Demand

Where GLP-1 demand is highest in Indiana

More than 38% of Indiana adults have obesity and about 14% have diagnosed diabetes (CDC BRFSS via America's Health Rankings, 2024), among the higher burdens nationally. Demand centers on Indianapolis. In a striking irony, Eli Lilly is headquartered in Indianapolis and is building a multibillion-dollar plant in Lebanon to make Mounjaro and Zepbound, so the GLP-1s many Indiana residents cannot get covered for weight loss are produced in their own state.

Questions

Indiana GLP-1 FAQ

Compound Guides

The GLP-1s behind these programs

Sources

How we sourced this page

Coverage, prevalence, and policy figures are drawn from primary and authoritative sources, last reviewed June 2026.